Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
RGNX
Stock Latest News
The Fly
FDA’s ‘surprising’ uniQure reversal drags down Biohaven
1d ago
BHVN
QURE
Premium
Ratings
RegenXBio’s Strong Position in Biotechnology Justifies Buy Rating Amid Gene Therapy Uncertainties
1d ago
RGNX
Premium
The Fly
FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel
1d ago
QURE
RGNX
Premium
The Fly
Regenxbio completes enrollment in Duchenne trial, begins RGX-202 production
6d ago
RGNX
Premium
Company Announcements
RegenXBio’s RGX-202 Gene Therapy: A Promising Step for Duchenne Muscular Dystrophy
8d ago
RGNX
Premium
Company Announcements
RegenXBio’s RGX-202: Promising Long-term Study for Duchenne Muscular Dystrophy
8d ago
RGNX
Premium
Company Announcements
RegenXBio’s New Study: A Step Forward in DMD Research
8d ago
RGNX
Premium
The Fly
Regenxbio completes enrollment in Atmosphere, Ascent pivotal studies
30d ago
RGNX
Premium
Ratings
Promising Data and Regulatory Progress Bolster Buy Rating for RegenXBio’s RGX-121
2M ago
RGNX
Premium
Ratings
Promising Data and Strategic Moves Position RegenXBio for Potential Success with RGX-121
2M ago
RGNX
Premium
The Fly
Regenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trial
2M ago
RGNX
Premium
The Fly
Regenxbio FDA delay ‘not a needle mover,’ says Leerink
3M ago
RGNX
Premium
Ratings
Strategic Developments and Partnerships Bolster RegenXBio’s Buy Rating Amid Regulatory Delay
3M ago
RGNX
Premium
Ratings
Optimistic Buy Rating for RegenXBio Amidst Promising Gene Therapy Developments
3M ago
RGNX
Premium
Company Announcements
FDA Extends Review for RegenXBio’s RGX-121 Therapy
3M ago
8K
RGNX
Premium
The Fly
Regenxbio announces FDA review extension for RGX-121 BLA
3M ago
RGNX
Premium
The Fly
Regenxbio price target lowered to $17 from $21 at RBC Capital
3M ago
RGNX
Premium
The Fly
Regenxbio price target lowered to $37 from $50 at Barclays
3M ago
RGNX
Premium
Company Announcements
REGENXBIO Reports Q2 2025 Financial Results and Progress
3M ago
RGNX
Premium
The Fly
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
3M ago
ABBV
RGNX
Premium
Company Announcements
RegenXBio and AbbVie Amend Collaboration Agreement
3M ago
8K
RGNX
Premium
The Fly
Regenxbio reports Q2 EPS ($1.38) vs. ($1.05) last year
3M ago
RGNX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
